During the past decade, Hallym University Sacred Heart Hospital conducted 27 clinical trials. In the 10-year time frame, 27 clinical trials started and 13 clinical trials were completed, i.e. on average, 48.1% percent of trials that started reached the finish line to date. In the past 5 years, 10 clinical trials started and 9 clinical trials were completed. i.e. 90% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hallym University Sacred Heart Hospital" #1 sponsor was "Hallym University Medical Center" with 11 trials, followed by "Seung-Jung Park" with 7 trials sponsored, "Pfizer" with 5 trials sponsored, "Bayer" with 3 trials sponsored and "Boehringer Ingelheim" with 3 trials sponsored. Other sponsors include 17 different institutions and companies that sponsored additional 24 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hallym University Sacred Heart Hospital" #1 collaborator was "CardioVascular Research Foundation, Korea" with 6 trials as a collaborator, "Ferring Pharmaceuticals Korea, Ltd." with 2 trials as a collaborator, "Solasia Pharma K.K." with 2 trials as a collaborator, "Australasian Gastro-Intestinal Trials Group" with 1 trials as a collaborator and "BeiGene, Ltd." with 1 trials as a collaborator. Other collaborators include 5 different institutions and companies that were collaborators in the rest 15 trials.

According to Clinical.Site data, the most researched conditions in "Hallym University Sacred Heart Hospital" are "Coronary Artery Disease" (7 trials), "Colorectal Cancer" (3 trials), "Gastric Cancer" (3 trials), "Anesthesia" (2 trials) and "Chemotherapy-induced Peripheral Neuropathy" (2 trials). Many other conditions were trialed in "Hallym University Sacred Heart Hospital" in a lesser frequency.

Most popular intervention types in "Hallym University Sacred Heart Hospital" are "Drug" (28 trials), "Device" (10 trials), "Other" (4 trials), "Procedure" (3 trials) and "Biological" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (9 trials), "Calmangafodipir (5 µmol/kg)" (2 trials), "Capecitabine" (2 trials), "Cypher" (2 trials) and "Dexmedetomidine" (2 trials). Other intervention names were less common.

The vast majority of trials in "Hallym University Sacred Heart Hospital" are 44 trials for "All" genders, 3 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "Hallym University Sacred Heart Hospital". undefined are not yet recruiting, 5 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 31 completed trials in Hallym University Sacred Heart Hospital, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Hallym University Sacred Heart Hospital, 1 "Phase 1" clinical trials were conducted, 7 "Phase 2" clinical trials and 13 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 13 trials, and there were also 10 trials that are defined as “Not Applicable".